It was a pleasure to talk with Professor Eric Morand (Monash Health, Monash University, Melbourne, VIC, Australia) to discuss the efficacy and safety findings from the PAISLEY study (ClinicalTrials.gov Identifier: NCT03252587), which investigated the TYK2 inhibitor deucravacitinib in the treatment of systemic lupus erythematosus.
The abstract ‘Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients With Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study‘ (Abstract number: LB0004) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
Questions
- What are the unmet needs in the treatment of systemic lupus erythematosus (SLE)? (0:11)
- What is deucravacitinib and what is the rationale for its use in the treatment of SLE? (0:49)
- What were the aims, design and eligibility of the PAISLEY study? (1:35)
- How well were the efficacy and safety endpoints achieved? (2:47)
- What will be the next step in the clinical development of deucravacitinib in this indication? (4:30)
Disclosures: Eric Morand discloses consulting for BristolMyersSquibb and receiving grant/ research support from BristolMyersSquibb.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
